Loss of the Antiangiogenic Pigment Epithelium-Derived Factor in Patients With Angiogenic Eye Disease
Article Figures & Tables
Figures
- FIG. 1.
Western blots with a polyclonal PEDF/EPC-1 antibody. Lanes 1-3 represent a typical standard curve with a dilution of recombinant PEDF (lane 1, undiluted; lane 2, 1:2 dilution; lane 3, 1:4 dilution). M, molecular size marker. A: The PEDF bands in lanes 1–-3 were reduced or disappeared after preincubation of the antibody with recombinant PEDF (lanes 4–-6), thereby demonstrating the specificity of the reaction. B: Western blot of vitreal samples of control subject (C), patients with PDR (D), and patients with severe intraocular neovascularization (Rubeosis iridis) caused by central-vein occlusion (R).
- FIG. 2.
Levels of vitreal PEDF in patients with proliferating eye disease. PEDF levels in intraocular samples from numerous patients were determined by Western blot analysis and compared with a standard concentration of purified human recombinant PEDF. The influence of intraocular activity was investigated by comparing levels of intraocular PEDF in patients with different degrees of neovascular activity: control subjects without angiogenesis, patients with quiescent PDR, patients with active PDR, and nondiabetic patients with extensive retinal neovascularization caused by central-vein occlusion (Rubeosis).
- FIG. 3.
Levels of vitreal PEDF depend on previous photocoagulation. PEDF levels were determined as described in Fig. 2 for patients with PDR − PRP, PDR + PRP, and Rubeosis, as well as nondiabetic patients with extensive retinal neovascularization due to central vein occlusion (control subjects).
- FIG. 4.
Concentrations of PEDF in human vitreous depending on localization of neovasularization. PEDF levels were determined as described in Fig. 2. Levels of PEDF correlate with the localization of retinal neovascularization. We compared patients without retinal angiogenesis (control subjects), patients with NVD, those with NVE, and those with both NVE and NVD.
- FIG. 5.
PEDF protein expression in retinal samples from patients with different stages of diabetic retinopathy. Human retinas were examined by immunohistochemistry for PEDF expression. Staining patterns for representative sections are shown for control subjects (A), patients with diabetes without ocular abnormalities (B), and patients with NPDR (C) compared with patients with PDR (D) and patients with quiescent PDR after retinal photocoagulation (E). Specificity of reaction was demonstrated by the absence of staining after incubating sections with the primary antibody that was preabsorbed with the recombinant antigen (F).
In this Issue
